These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37723133)

  • 21. Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
    Yunusa I; Love BL
    Am J Gastroenterol; 2023 Apr; 118(4):635-644. PubMed ID: 36693030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
    Sue S; Kuwashima H; Iwata Y; Oka H; Arima I; Fukuchi T; Sanga K; Inokuchi Y; Ishii Y; Kanno M; Terada M; Amano H; Naito M; Iwase S; Okazaki H; Komatsu K; Kokawa A; Kawana I; Morimoto M; Saito T; Kunishi Y; Ikeda A; Takahashi D; Miwa H; Sasaki T; Tamura T; Kondo M; Shibata W; Maeda S
    Intern Med; 2017; 56(11):1277-1285. PubMed ID: 28566587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
    Du RC; Ouyang YB; Lu NH; Hu Y
    Helicobacter; 2023 Oct; 28(5):e13012. PubMed ID: 37515414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
    Poonyam P; Chotivitayatarakorn P; Vilaichone RK
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2859-2864. PubMed ID: 31554388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.
    Hu Y; Xu X; Ouyang YB; He C; Li NS; Xie C; Peng C; Zhu ZH; Xie Y; Shu X; Lu NH; Zhu Y
    Helicobacter; 2022 Aug; 27(4):e12896. PubMed ID: 35466521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study: Vonoprazan and proton pump inhibitors in
    Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
    World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
    Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
    Hirata Y; Yamada A; Niikura R; Shichijo S; Hayakawa Y; Koike K
    Helicobacter; 2020 Oct; 25(5):e12719. PubMed ID: 32602161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
    Choe JW; Jung SW; Kim SY; Hyun JJ; Jung YK; Koo JS; Yim HJ; Lee SW
    Helicobacter; 2018 Apr; 23(2):e12466. PubMed ID: 29369454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
    Yu L; Luo L; Long X; Liang X; Ji Y; Graham DY; Lu H
    Helicobacter; 2019 Aug; 24(4):e12596. PubMed ID: 31111580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.
    Shinmura T; Adachi K; Yamaguchi Y; Izawa S; Hijikata Y; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):389-395. PubMed ID: 31826057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial.
    Hu Y; Huang XH; Zhou B; Liu ML; Liu YF; Yu T; Sun P; Tan BB; Hu Y; Cheng F; Pan XL; Hong JB; Shu X; Zhu Y; Lu NH
    Helicobacter; 2024; 29(1):e13045. PubMed ID: 39191423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
    Kiliç ZM; Köksal AS; Cakal B; Nadir I; Ozin YO; Kuran S; Sahin B
    Dig Dis Sci; 2008 Dec; 53(12):3133-7. PubMed ID: 18465244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
    Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
    Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
    Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
    Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
    J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
    Peng X; Chen HW; Wan Y; Su PZ; Yu J; Liu JJ; Lu Y; Zhang M; Yao JY; Zhi M
    Clin Exp Med; 2023 Nov; 23(7):4011-4019. PubMed ID: 37115412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
    Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
    Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.